Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06687590 · ClinicalTrials.gov registry record
Serranator POINT FORCE Registry
A clinical trial of Peripheral Artery Disease (PAD) and Dysfunctional AV Fistula, sponsored by Cagent Vascular.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT06687590 is a study of Peripheral Artery Disease (PAD) and Dysfunctional AV Fistula that is actively recruiting participants, run by Cagent Vascular. The registered enrollment target is 500 participants, above the 189-participant average among 5 other Peripheral Artery Disease (PAD) trials with a reported enrollment target (165% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06687590, a study of Peripheral Artery Disease (PAD) and Dysfunctional AV Fistula, is actively recruiting participants, sponsored by Cagent Vascular.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this registry is to collect observational data under local standard of care and evaluate safety and performance of the Serranator® in treatment of peripheral artery disease (PAD), or dysfunctional native or synthetic arteriovenous dialysis fistulae in a real-world scenario. The data and conclusions derived from this study will be used to provide clinical evidence for the clinical evaluation process.
Conditions Studied
Interventions
- DEVICE Peripheral balloon angioplasty
Study Locations (1)
Texas
- UT Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-01-22 |
| Est. Completion | 2026-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06687590
The ClinicalTrials.gov registry entry for NCT06687590 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 189-participant average among 5 other Peripheral Artery Disease (PAD) trials with a reported enrollment target (165% higher). The listed sponsor is Cagent Vascular, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Peripheral Artery Disease (PAD) appearing as the primary indexed condition, and to 1 intervention - of which Peripheral balloon angioplasty is the first listed.
NCT06687590 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06687590 about?
NCT06687590 is a clinical study titled "Serranator POINT FORCE Registry". The objective of this registry is to collect observational data under local standard of care and evaluate safety and performance of the Serranator® in treatment of peripheral artery disease (PAD), or dysfunctional native or synthetic arteriovenous dialysis fistulae in a real-world scenario. The dat...
What is the current status of trial NCT06687590?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2025-01-22. Estimated completion is 2026-12-31.
What conditions does trial NCT06687590 study?
This clinical trial studies the following conditions: Peripheral Artery Disease (PAD), Dysfunctional AV Fistula, Dysfunctional AV Graft.
What interventions are being tested in trial NCT06687590?
The interventions under investigation include: Peripheral balloon angioplasty (DEVICE).
Who is sponsoring clinical trial NCT06687590?
This trial is sponsored by Cagent Vascular, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06687590 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Artery Disease (PAD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
RECRUITING · Phase 2
-
Detecting Peripheral Artery Disease With the Pulse
RECRUITING · NA
-
Using Near-Infrared Light to Better Understand Peripheral Artery Disease
RECRUITING
-
The Chocolate Touch Study
ACTIVE NOT RECRUITING · NA
-
A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.